JPRN-jRCT2080220606未知2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Key Criteria for inclusion
- •The subject has been taking metformin at a stable dose regimen for at least 12 weeks prior to the initiation of the treatment period (Week 0).
- •The subject has an HbA1c of 6.5% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).
排除标准
- •Key Criteria for exclusion
- •The subject has taken other diabetic medications than metformin within 12 weeks before the initiation of the treatment period (Week 0).
- •The subject with a history or symptoms of lactic acidosis.
研究者
相似试验
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineJPRN-jRCT2080220568Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineType 2 diabetes mellitusJPRN-UMIN000001382Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitus.JPRN-jRCT2080220603Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitusJPRN-UMIN000001393Takeda Pharmaceutical Company Limited240